Literature DB >> 22187072

Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options.

Corey A Siegel1.   

Abstract

The treatment of inflammatory bowel disease is becoming more complicated with new medications and new treatment paradigms. Although data are accumulating that the earlier use of immunomodulators and anti-tumor necrosis factor agents are more effective than the standard "step-up" pyramidal treatment algorithm, patients may not be comfortable with this more intensive therapeutic approach. The process of shared decision making engages patients in treatment decisions to optimize the chance that a chosen therapy matches their personal preferences for care. Decision aids are standard shared decision making tools, which are used to present evidence-based data in a patient-friendly manner to help patients with preference-sensitive decisions. Not all care decisions are preference-sensitive, and not all patients are interested in being part of a shared medical decision. The responsibility of the provider is to identify how much of a role patients want, and then determine which decisions need their input to provide the best patient-centered care. The overall goal is to involve patients in decisions so that they are educated about their options, confident in the plan, adherent to chosen therapy and ultimately have a better quality of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187072     DOI: 10.1136/gutjnl-2011-300988

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

Review 1.  Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease.

Authors:  David T Rubin; Noa Krugliak Cleveland
Journal:  Am J Gastroenterol       Date:  2015-04-07       Impact factor: 10.864

2.  Optimizing perioperative Crohn's disease management: role of coordinated medical and surgical care.

Authors:  Jennifer L Bennett; Christina Y Ha; Jonathan E Efron; Susan L Gearhart; Mark G Lazarev; Elizabeth C Wick
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  Patient decision tools in inflammatory bowel disease.

Authors:  Corey A Siegel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-09

4.  Optimizing the Use of Biologic Therapies in the Management of Inflammatory Bowel Disease.

Authors:  Gerald W Dryden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-12

Review 5.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

6.  Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.

Authors:  Christopher V Almario; Michelle S Keller; Michelle Chen; Karen Lasch; Lyann Ursos; Julia Shklovskaya; Gil Y Melmed; Brennan M R Spiegel
Journal:  Am J Gastroenterol       Date:  2017-12-05       Impact factor: 10.864

7.  Shared Decision Making About Starting Anti-TNFs: A Pediatric Perspective.

Authors:  Hilary K Michel; Robert B Noll; Nalyn Siripong; Sandra C Kim; Ellen A Lipstein
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-03       Impact factor: 2.839

8.  Patient preferences for surgical versus medical therapy for ulcerative colitis.

Authors:  Meenakshi Bewtra; Vikram Kilambi; Angelyn O Fairchild; Corey A Siegel; James D Lewis; F Reed Johnson
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

Review 9.  Distance management of inflammatory bowel disease: systematic review and meta-analysis.

Authors:  Vivian W Huang; Krista M Reich; Richard N Fedorak
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 10.  Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease.

Authors:  Parambir S Dulai; Corey A Siegel; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.